The Street Insider May 16, 2013
Article :Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society Of Clinical Oncology Annual Meeting
BY PR Newswire | 05/16/13
Stock quotes in this article: HALO
"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu, M.D., Ph.D., Vice President,Oncology Clinical Development, Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion.
just bought in. Will be a major biotech.
Seeking Alpha Currents 5/16/13
Halozyme Therapeutics (HALO) Data from aPhase 1b study supports the contention that PEGPH20 helps break down a protective matrix which surrounds most pancreatic cancers, making the disease more vulnerable to therapy
chart read is correct also showing breakout just beginning, going north.
listened to call twice and does say just need the documents.
paste and google from today.
nothing about any other meetings. Nice.
take advantage of that.
are posts working ??????